Abstract
Aim:
To study the protective effects of a triptolide-derived, novel compound, (5R)-5-hydroxytriptolide (LLDT-8), on bleomycin-induced lung fibrosis.
Methods:
C57BL/6 mice received an intratracheal injection of bleomycin and were then treated with LLDT-8 (0.5, 1, 2 mg/kg, ip) once daily for 7 or 14 consecutive days. The body weight loss and lung index augmentation was observed; the inflammatory response including differential cells counts of neutrophils, macrophages, and lymphocytes in the bronchoalveolar lavage fluid (BALF), superoxide dismutase (SOD), and malondialdehyde (MDA) level in the lung homogenates was detected, and the fibrosis extent was evaluated by hydroxyproline content and histopathological changes in the lungs. In addition, the pro-inflammatory and pro-fibrotic cytokines, tumor necrosis factor-α (TNF-α), interleukin-4 (IL-4), and transforming growth factor-α (TGF-α) production in the lungs were measured.
Results:
LLDT-8 alleviated the body weight loss and lung index increase caused by bleomycin, reduced neutrophils and lymphocytes in the BALF, promoted SOD activity, decreased MDA production, and inhibited the hydroxyproline level and the amelioration of lung tissue histological damage. Moreover, LLDT-8 suppressed TNF-α, IL-4, and TGF-β production in the lung homogenates.
Conclusion:
LLDT-8 showed protective effects against bleomycin-induced lung fibrosis, and the results suggested the potential role of LLDT-8 in the treatment of this disease.
Similar content being viewed by others
Article PDF
References
Gharaee-Kermani, M, Phan, SH, Molecular mechanisms of and possible treatment strategies for idiopathic pulmonary fibrosis. Curr Pharm Des 2005; 11: 3943–71.
Khalil, N, O'Connor, R, Idiopathic pulmonary fibrosis: current understanding of the pathogenesis and the status of treatment. Can Med Assoc J 2004; 171: 153–60.
Gross, TJ, Hunninghake, GW, Idiopathic pulmonary fibrosis. N Engl J Med 2001; 345: 517–25.
Ozyurt, H, Sogut, S, Yildirim, Z, Kart, L, Iraz, M, Armutcu, F, et al. Inhibitory effect of caffeic acid phenethyl ester on bleomycin-induced lung fibrosis in rats. Clin Chim Acta 2004; 339: 65–75.
Asano, K, Matsuishi, J, Yu, Y, Kasahara, T, Hisamitsu, T, Suppressive effects of Tripterygium wilfordii Hook f., a traditional Chinese medicine, on collagen arthritis in mice. Immunopharmacology 1998; 39: 117–26.
Gu, WZ, Banerjee, S, Rauch, J, Brandwein, SR, Suppression of renal disease and arthritis, and prolongation of survival in MRL-lpr mice treated with an extract of Tripterygium wilfordii Hook f. Arthritis Rheum 1992; 35: 1381–6.
Gu, WZ, Brandwein, SR, Inhibition of type II collagen-induced arthritis in rats by triptolide. Int J Immunopharmacol 1998; 20: 389–400.
Tao, X, Davis, LS, Hashimoto, K, Lipsky, PE, The Chinese herbal remedy, T2, inhibits mitogen-induced cytokine gene transcription by T cells, but not initial signal transduction. J Pharmacol Exp Ther 1996; 276: 316–25.
Chen, BJ, Triptolide, a novel immunosuppressive and anti-inflammatory agent purified from a Chinese herb Tripterygium wilfordii Hook F. Leuk Lymphoma 2001; 42: 253–65.
Huynh, PN, Hikim, AP, Wang, C, Stefonovic, K, Lue, YH, Leung, A, et al. Long-term effects of triptolide on spermatogenesis, epididymal sperm function, and fertility in male rats. J Androl 2000; 21: 689–99.
Zhou, R, Zhang, F, He, PL, Zhou, WL, Wu, QL, Xu, JY, et al. (5R)-5-hydroxytriptolide (LLDT-8), a novel triptolide analog mediates immunosuppressive effects in vitro and in vivo. Int Immunopharmacol 2005; 5: 1895–903.
Zhou, R, Tang, W, Ren, YX, He, PL, Zhang, F, Shi, LP, et al. (5R)-5-hydroxytriptolide attenuated collagen-induced arthritis in DBA/ 1 mice via suppressing interferon-gamma production and its related signaling. J Pharmacol Exp Ther 2006b; 318: 35–44.
Tang, W, Yang, Y, Zhang, F, Li, YC, Zhou, R, Wang, JX, et al. Prevention of graft-versus-host disease by a novel immunosuppressant, (5R)-5-hydroxytriptolide (LLDT-8), through expansion of regulatory T cells. Int Immunopharmacol 2005; 5: 1904–13.
Tang, W, Zhou, R, Yang, Y, Li, YC, Yang, YF, Zuo, JP, Suppression of (5R)-5-hydroxytriptolide (LLDT-8) on allograft rejection in full MHC-mismatched mouse cardiac transplantation. Transplantation 2006; 81: 927–33.
Zhou, R, Tang, W, Ren, YX, He, PL, Yang, YF, Li, YC, et al. Preventive effects of (5R)-5-hydroxytriptolide on concanavalin A-induced hepatitis. Eur J Pharmacol 2006a; 537: 181–9.
Kremer, S, Brever, R, Lossos, IS, Effect of immunomodulators on bleomycin-induced lung injury. Respiration 1999; 66: 455–62.
Li, XF, Takiuchi, H, Zou, JP, Katagiri, T, Yamamoto, N, Nagata, T, et al. Transforming growth factor-β (TGF-β)-mediated immunosuppression in the tumor-bearing state: enhanced production of TGF-β and a progressive increase in TGF-β susceptibility of anti-tumor CD4+ T cell function. Jpn J Cancer Res 1993; 84: 315–25.
Borzone, G, Moreno, R, Urrea, R, Meneses, M, Oyarzun, M, Bleomycin-induced chronic lung damage does not resemble human idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2001; 163: 1648–53.
Tarnell, EB, Oliver, BL, Johnson, GM, Watts, FL, Thrall, RS, Superoxide anion production by rat neutrophils at various stages of bleomycin-induced lung injury. Lung 1992; 170: 41–50.
Oury, TD, Thakker, K, Menache, M, Chang, LY, Crapo, JD, Day, BJ, Attenuation of bleomycin-induced pulmonary fibrosis by a catalytic antioxidant metalloporphyrin. Am J Respir Crit Care Med 2001; 164: 164–9.
Kinnula, VL, Fattman, CL, Tan, RJ, Oury, TD, Oxidative stress in pulmonary fibrosis. Am J Respir Crit Care Med 2005; 172: 417–22.
Kuwanl, K, Nakashima, N, Inoshima, I, Hagimoto, N, Fujita, M, Yoshimi, M, et al. Oxidative stress in lung epithelial cells from patients with idiopathic interstitial pneumonias. Lab Invest 2002; 82: 1695–706.
Bellocq, A, Azoulay, C, Marullo, S, Flahault, A, Fouqueray, B, Philippe, C, et al. Reactive oxygen and nitrogen intermediates increase transforming growth factor-beta 1 release from human epithelial alveolar cells through two different mechanisms. Am J Respir Cell Mol Biol 1999; 21: 128–36.
Salvemini, D, Riley, DP, Cuzzocrea, S, SOD mimetics are coming of age. Nat Rev Drug Discov 2002; 1: 367–74.
Piguet, PF, Ribaux, C, Karpuz, V, Grau, GE, Kapanci, Y, Expression and localization of tumor necrosis factor-alpha and its mRNA in idiopathic pulmonary fibrosis. Am J Pathol 1993; 143: 651–5.
Yara, S, Kawakami, K, Kudeken, N, Tohyama, M, Teruya, K, Chinen, T, et al. FTS reduced bleomycin-induced cytokine and chemokine production and inhibits pulmonary fibrosis in mice. Clin Exp Immunol 2001; 124: 77–85.
Walter, N, Collard, HR, King, TE Jr, Current perspectives on the treatment of idiopathic pulmonar fibrosis. Proc Am Thorac Soc 2006; 3: 330–8.
Izbicki, G, Segel, MJ, Christensen, TG, Conner, MW, Breuer, R, Time course of bleomycin-induced lung fibrosis. Int J Exp Path 2002; 83: 111–9.
Gharaee-Kermani, M, Phan, SH, Role of cytokines and cytokine therapy in wound healing and fibrotic diseases. Curr Pharm Des 2001; 11: 1083–103.
Lossos, IS, Or, R, Goldstein, RH, Conner, MW, Breuer, R, Amelioration of bleomycin-induced pulmonary injury by cyclosporin A. Exp Lung Res 1996; 22: 337–49.
Zhu, J, Cohen, DA, Goud, SN, Kaplan, AM, Contribution of T lymphocytes to the development of bleomycin-induced pulmonary fibrosis. Ann NY Acad Sci 1996; 796: 194–202.
Sharma, SK, MacLean, JA, Pinto, C, Kradin, RL, The effect of an anti-CD3 monoclonal antibody on bleomycin-induced lymphokine production and lung injury. Am J Respir Crit Care Med 1996; 154: 193–200.
Huaux, F, Liu, T, McGarry, B, Ullenbruch, M, Phan, SH, Dual roles of IL-4 in lung injury and fibrosis. J Immunol 2003; 170: 2083–92.
Arai, T, Abe, K, Matsuoka, H, Yoshida, M, Mori, M, Goya, S, et al. Introduction of the interleukin-10 gene into mice inhibited bleomycin-induced lung injury in vivo. Am J Physiol Lung Cell Mol Physiol 2000; 278: L914–22.
Sakamoto, H, Zhao, LH, Jain, F, Kradin, R, IL-12p40(-/-) mice treated with intratracheal bleomycin exhibit decreased pulmonary inflammation and increased fibrosis. Exp Mol Pathol 2002; 72: 1–9.
Gharaee-Kermani, M, Nozaki, Y, Hatano, K, Phan, SH, Lung interleukin-4 gene expression in a murine model of bleomycin-induced pulmonary fibrosis. Cytokine 2001; 15: 138–47.
Krishna, G, Liu, K, Shigemitsu, H, Gao, M, Raffin, TA, Rosen, GD, PG490–88, a derivative of triptolide, blocks bleomycin-induced lung fibrosis. Am J Pathol 2001; 158: 997–1004.
Author information
Authors and Affiliations
Corresponding author
Additional information
This work was supported by grants from the Knowledge Innovation Program of the Chinese Academy of Sciences (No KSCX2-SW-202) and the Shanghai Science and Technology Committee (No 03DZ19228)
Rights and permissions
About this article
Cite this article
Ren, Yx., Zhou, R., Tang, W. et al. (5R)-5-hydroxytriptolide (LLDT-8) protects against bleomycin-induced lung fibrosis in mice. Acta Pharmacol Sin 28, 518–525 (2007). https://doi.org/10.1111/j.1745-7254.2007.00524.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2007.00524.x
Keywords
This article is cited by
-
(5R)-5-Hydroxytriptolide (LLDT-8) induces substantial epigenetic mediated immune response network changes in fibroblast-like synoviocytes from rheumatoid arthritis patients
Scientific Reports (2019)
-
Immunosuppressant discovery from Tripterygium wilfordii Hook f: the novel triptolide analog (5R)-5-hydroxytriptolide (LLDT-8)
Acta Pharmacologica Sinica (2012)
-
LLDT-67 attenuates MPTP-induced neurotoxicity in mice by up-regulating NGF expression
Acta Pharmacologica Sinica (2012)